Office of Blood, Organ, and Other Tissue Safety, Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Division of Infectious Disease and Geographic Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Am J Transplant. 2021 May;21(5):1911-1923. doi: 10.1111/ajt.16433. Epub 2021 Feb 2.
Cryptococcus species can cause serious life-threatening infection in solid organ transplant recipients by reactivation of prior infection, posttransplant de novo infection, or donor transmission from the transplanted organ. Although previously reported in the literature, the extent of donor-derived cryptococcosis in the United States has not been documented. We analyzed potential donor-derived Cryptococcus transmission events reported to the Organ Procurement and Transplantation Network (OPTN) for investigation by the Ad Hoc Disease Transmission Advisory Committee (DTAC). All reports between 2009 and 2019 in which transmission to recipients was designated proven or probable, or determined to be averted due to implementation of prophylaxis (intervention without disease transmission-"IWDT") were included. During 2009-2019, 58 reports of potential donor-derived cryptococcosis were submitted to DTAC. Among these reports, 12 donors were determined to have resulted in proven or probable transmission to 23/34 (67.6%) recipients. Most of these donors (10/12 [83%]) exhibited central nervous system-related symptoms prior to death and 5/23 (22%) infected recipients died. For 11 different donors, prophylaxis, most often with fluconazole, was administered to 23/35 (65.7%) recipients. Clinicians should maintain awareness of donor-derived cryptococcosis and consider prompt prophylaxis or treatment followed by reporting to OPTN for further investigation.
隐球菌属物种可通过先前感染的再激活、移植后新发感染或供体从移植器官传播,在实体器官移植受者中引起严重危及生命的感染。虽然以前在文献中报道过,但美国供体来源的隐球菌病的程度尚未记录。我们分析了向器官获取与移植网络(OPTN)报告的供体潜在来源隐球菌传播事件,以供临时疾病传播咨询委员会(DTAC)调查。所有在 2009 年至 2019 年期间报告的传播给受者的病例中,传播被指定为证实或可能,或由于实施预防措施(无疾病传播的干预措施-IWDT)而被避免的病例均包括在内。在 2009-2019 年期间,向 DTAC 提交了 58 份潜在供体来源隐球菌病报告。在这些报告中,有 12 名供体被确定导致 23/34(67.6%)受者发生证实或可能的传播。这些供体中的大多数(10/12 [83%])在死亡前表现出中枢神经系统相关症状,5/23(22%)受感染的受者死亡。对于 11 个不同的供体,23/35(65.7%)受者接受了预防治疗,最常用氟康唑。临床医生应保持对供体来源隐球菌病的认识,并考虑及时进行预防或治疗,然后向 OPTN 报告以进一步调查。